A compilation of 13 patients with metastatic colorectal cancer and concomitant <i>BRAF</i> and <i>RAS</i> family mutations.

ABSTRACT:

Introduction

Metastatic colorectal cancer (mCRC) exhibits significant heterogeneity in molecular profiles, influencing treatment response and patient outcomes. Mutations in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and rat sarcoma (RAS) family genes are commonly observed in mCRC. Though originally thought to be mutually exclusive, recent data have shown that patients may present with concomitant RAS and BRAF mutations, posing unique challenges and implications for clinical management.

Methods

Below we present a retrospective study on 13 patients with concomitant BRAF and RAS (KRAS, NRAS) mutations in mCRC and describe their clinical features and treatment outcomes. We reviewed over 750 samples from a database of CR

SUBMITTER: Srivastav J 

PROVIDER: S-EPMC12414759 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature